Bruce Willis has frontotemporal dementia, commonly called FTD. His family first announced in March 2022 that he had been diagnosed with aphasia, a condition that impairs the ability to speak and understand language. Ten months later, on February 16, 2023, they shared a more specific diagnosis: frontotemporal dementia. The updated diagnosis explained the root cause of his language difficulties and led to his full retirement from acting.
How FTD Differs From Alzheimer’s
Most people hear “dementia” and think of Alzheimer’s disease, but frontotemporal dementia is a distinct condition that typically strikes earlier in life. Alzheimer’s primarily attacks memory first. FTD, by contrast, damages the frontal and temporal lobes of the brain, the regions responsible for personality, behavior, decision-making, and language. People with FTD often retain their ability to do basic math, recognize places, and draw simple figures well into the disease, while struggling with speech or social behavior in ways that can look nothing like Alzheimer’s.
FTD is the most common form of dementia in people under 60, though it can occur later as well. Bruce Willis was 67 when his family disclosed the aphasia diagnosis. Because early symptoms often involve personality shifts or language trouble rather than the classic memory loss people associate with dementia, FTD is frequently misdiagnosed as a psychiatric condition or simply overlooked for years.
What Happens in the Brain
In FTD, neurons in the frontal and temporal lobes gradually die, causing those areas of the brain to physically shrink over time. Scientists have identified two proteins at the center of this destruction: tau and TDP-43. In a healthy brain, both proteins serve normal functions. In FTD, they misfold or accumulate in abnormal amounts, forming clumps that poison and eventually kill nerve cells. Which protein is involved, and where the damage concentrates, determines which symptoms appear first.
About 30% of FTD cases are genetic, linked to inherited mutations in specific genes. People with the behavioral variant of FTD are four times more likely to have a strong family history compared to those whose language is affected first. For the remaining cases, the trigger is not well understood.
The Language Variant Bruce Willis Experienced
FTD presents in several ways. The four main subtypes are the behavioral variant, progressive nonfluent aphasia, semantic dementia, and logopenic progressive aphasia. Bruce Willis’s condition began with aphasia, meaning language was the first ability to deteriorate. In this form, sometimes called primary progressive aphasia, a person gradually loses the capacity to find words, form sentences, or understand spoken language, while other cognitive abilities like spatial reasoning may remain relatively intact for a time.
Primary progressive aphasia was formally defined as a condition where language steadily declines for at least two years before other cognitive problems appear. For someone like Willis, whose career depended entirely on delivering dialogue, the impact would have been apparent early. Reports from film sets in his final years described him struggling to remember and deliver lines, which aligns with the progressive language breakdown characteristic of this form of FTD.
The behavioral variant looks quite different. Instead of language problems, people develop changes in personality and social conduct: loss of inhibition, poor impulse control, inappropriate comments, neglect of personal hygiene, rigid or repetitive behaviors, or a striking loss of motivation and initiative. Some patients develop unusual new interests, compulsive eating patterns, or even a sudden surge in artistic tendencies. These symptoms are often mistaken for depression or other psychiatric conditions before the true diagnosis becomes clear.
Progression and Prognosis
FTD is a progressive disease, meaning symptoms worsen over time as more brain tissue is lost. The Willis family acknowledged this directly in their 2023 statement, noting that Bruce’s condition had progressed since the initial aphasia announcement. Average survival from symptom onset is roughly 8 to 9 years, comparable to Alzheimer’s, though the range varies considerably by subtype. People with semantic dementia tend to live longest, averaging around 11 years, while progressive nonfluent aphasia, the language-first form, averages about 8.5 years. Cases where FTD overlaps with motor neuron disease have the shortest survival, closer to 3 years.
These are averages drawn from large studies, and individual experiences vary. The pace of decline depends on which brain regions are affected, the underlying protein pathology, and the person’s overall health. Over time, most forms of FTD eventually affect both language and behavior as the damage spreads beyond its initial focus.
No Cure Exists Yet
There are currently no approved treatments that can stop, slow, or reverse frontotemporal dementia. Treatment is entirely focused on managing symptoms. The medications used for Alzheimer’s, such as cholinesterase inhibitors, have not proven effective for FTD. Care typically involves speech therapy to maintain communication as long as possible, behavioral strategies to manage personality changes, and increasing levels of support as the disease progresses.
Several experimental therapies are in clinical trials. At least one drug targeting a specific genetic form of FTD has received breakthrough therapy designation from the FDA, and others have been granted orphan drug or fast-track status to speed development. These are promising steps, but none has reached the point of widespread availability.
Raising Awareness Through a Public Diagnosis
Before Willis’s diagnosis, FTD was largely unknown to the general public. His family chose to release their February 2023 statement through the Association for Frontotemporal Degeneration, a deliberate move to direct attention and resources toward the condition. The statement encouraged other families dealing with FTD to seek support through the organization and asked the broader public to learn about a disease that most people had never heard of.
Media analysis found that early coverage of Willis’s condition often reflected widespread unfamiliarity with FTD. Many outlets initially treated “aphasia” and “frontotemporal dementia” as separate diagnoses rather than recognizing that progressive aphasia is one of the ways FTD manifests. Clinicians familiar with primary progressive aphasia were unsurprised by the updated diagnosis, since language-first symptoms frequently turn out to be an early stage of frontotemporal degeneration. The public conversation around Willis’s health has since become one of the most significant drivers of FTD awareness.